Tagged with USA,

USA As the search for effective Alzheimer’s treatments continues to evolve, Annovis Bio is taking a distinct approach with buntanetap, a novel oral candidate designed to intervene more broadly in disease progression. In this interview, Chief Business Officer Mark White discusses the company’s clinical learnings, operational discipline, and the realities of…

USA While on the surface it may look like pharmaceuticals have been spared by Donald Trump’s “Liberation Day” trade policies, drugmakers still lack a clear picture of how they will be impacted. The US president has not, as of yet, imposed “25 percent or higher” tariffs as originally pledged, but that…

USA Peter Marks, the US FDA’s top official for vaccines and cell and gene therapies, has resigned. A survivor of the first Trump administration, when his office faced intense pressure to fast-track COVID vaccine approvals, Marks reportedly clashed with new Health and Human Services Secretary Robert F. Kennedy Jr. and his…

USA The Alzheimer’s Drug Discovery Foundation (ADDF) operates in the critical niche of translational research, attempting to bridge the “Valley of Death” between discovery and commercialisation using a venture philanthropy model that reinvests returns into new science. CEO Mark Roithmayr explains how the ADDF has helped launch major diagnostic tools for…

Ireland In the latest chapter of the trade disputes launched by Donald Trump, the US president has accused Ireland of “stealing” pharma tax revenue. The country’s low corporate tax rates have attracted American heavyweights like Pfizer and Eli Lilly in recent years, but could changes to tax policy and trade tariffs…

China Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by blacklisting the American gene sequencing giant. But beyond the implications for the company, as the trade conflict continues to rage…

USA David H. Crean, Ph.D., is a San Diego-based venture capitalist and strategic advisor with over 30 years of experience in life sciences and healthcare. Drawing on a deep personal connection to Alzheimer’s disease as well as decades of experience as a scientist and investor, Crean casts his eye over the…

USA The US pharmaceutical industry is scrambling to align with President Donald Trump’s policy agenda, but may not get all it wishes for…   In its first few weeks in power, the emboldened second Trump administration has enacted a scattergun set of executive orders, covering everything from swingeing cuts to the…

Puerto Rico Puerto Rico leads all US jurisdictions in biopharmaceutical exports, shipping to over 120 countries. With a rapidly expanding life sciences sector and growing pharma logistics capabilities, the island is positioning itself as a global hub—but industry leaders say there’s still work to be done.   Life Sciences and Logistics Dynamo…

USA Since Christopher Viehbacher took the reins of Biogen in 2022, he has launched a USD 1 billion cost-cutting and priority refocusing plan, made significant deals, and launched the firm’s Alzheimer’s drug Legembi. But snags slowing the uptake of the Eisai-partnered med and the fall in sales of its multiple sclerosis…

Saudi Arabia Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease.   As people live longer, the threat of age-related diseases deepens. Alzheimer’s, one of the cruellest such diseases, therefore represents an increasingly urgent public health challenge in…

Denmark As tensions rise over US-EU trade, will the weight-loss drug Ozempic become an unexpected bargaining chip? Stan Jackson explores the risks of leveraging GLP-1s in economic negotiations.   You can always tell when a blockbuster drug has entered the cultural zeitgeist. It’s around the time you start to hear the…